Respiratory Syncytial Virus Vaccines: The Future is Bright
Access Resources
About
This editorial describes the progress in developing vaccines for respiratory syncytial virus (RSV), a virus causing serious illness in infants and older adults. New vaccines and antibodies have shown success, with approvals in the US, UK, and Canada. However, vaccine uptake is low due to poor awareness and safety concerns. Real-world studies are needed to monitor effectiveness as countries roll out vaccination programs. The goal is to reduce RSV rates globally while ensuring affordable access for low-income countries. A tool predicting severe RSV risk in newborns may help allocate resources effectively.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.